Palexia - Key Visual

Your patients benefit from Palexia® PR

Palexia® PR provides:

  • 37% more pain reduction than oxycodone/ naloxone3
  • 40% less constipation than oxycodone/ naloxone*2,4
  • 77% more patients stay on Palexia® PR compared to oxycodone/ naloxone*4

WHO COULD BE YOUR NEXT PALEXIA® PR PATIENT?

Palexia - Key
Palexia - Key Visual - Efficacy

DIFFERENT FROM CLASSICAL OPIOIDS.
PALEXIA® MOR-NRI6,7

Palexia® - Tapentadol - MOR-NRI - Mechanism of action - Chart
Zoom

Palexia - Key Visual - Pain reduction

Recommended
dosing scheme Palexia® PRΔ1

Palexia® - Dosing scheme - Chart
Zoom

Palexia - Key Visual - Efficacy

Conversion to
Palexia® PR

Palexia® PR starting dose for patients on classic strong opioidse12

Palexia® - Conversion to Palexia® PR - Chart
Zoom

View footnotes

*in severe cLBP with a neuropathic pain component, compared to oxycodone/naloxone PR.

#Clinical Studies include: Phase III interventional trials – osteoarthritis knee pain13a; low back pain12a; 1-year safety (osteoarthritis, low back pain)14b; phase IIIb, chronic low back pain with or without a neuropathic component15c; (after conversion from prior WHO step III therapy)1c; chronic osteoarthritis knee pain16c; (after conversion from prior WHO step III therapy)17c. Non-interventional trial: severe chronic pain18d.
a Mean dose during the 12-week maintenance period;
b Mean dose over the 52-week study;
c Mean dose at Week 6 (the first week after titration);
d Mean dose at the final study visit.
e Provided doses ranges are based on information on conversion taken from the individual products’ prescribing information. An equianalgesic ratio for Palexia® PR vs oxycodone CR was derived from clinical phase III trials (tap:oxy ≈ 5:1)5,13 and is in line with equianalgesic information from a phase IIIb trials.14,19

ABBREVIATIONS
cLBP, chronic lower back pain
CR, controlled release
MOR, µ-opioid-receptor agonist
NP, neuropathic
NRI, noradrenaline reuptake inhibitor
PR, prolonged-release
WHO, world health organization